In keeping with current guidelines, either empagliflozin or dapagliflozin can be used for preventing AKI and CKD in patients with type 2 diabetes. Empagliflozin and dapagliflozin are equally effective ...

A new study shows that older adults with type 2 diabetes who start treatment with sodium–glucose cotransporter-2 (SGLT-2) ...

Among a small cohort of healthy Korean male volunteers, evogliptin combined with empagliflozin or dapagliflozin had no significant effects on the pharmacokinetics (PK) of each drug. In healthy male ...

Comparative effectiveness study followed adults with type 2 diabetes who initiated SGLT-2 inhibitors from 2014 to 2020. Real-world outcomes largely point to comparable risks of hospitalization for ...

The SGLT2 inhibitors, as a class, lead to similar treatment benefits at comparable clinical doses, although there are some discrepancies between them, particularly when dapagliflozin (Farxiga; ...

A new study shows that empagliflozin, the diabetes drug that set off a market frenzy 5 years ago, is on par with dapagliflozin for certain heart failure patients. Empagliflozin, the drug that stunned ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Topline findings from the phase 3 DELIVER ...

Please provide your email address to receive an email when new articles are posted on . The EMPEROR-Reduced data were published in The New England Journal of Medicine a day before scheduled ...

NATIONAL HARBOR, Md. -- The benefits of dapagliflozin (Farxiga) persisted in various secondary analyses of the DELIVER trial, building confidence for real-world benefits from the SGLT2 inhibitor for ...

In April 2021, dapagliflozin (Farxiga) received a new indication from the US Food and Drug Administration (FDA) for slowing progression of chronic kidney disease (CKD) in people without any other ...